XTalks

OCTOBER 28, 2024

Diabetes, a chronic condition marked by high blood glucose levels due to insulin issues, brings complications like heart disease, stroke, neuropathy and diabetic foot ulcers. Abbot also joined Medtronic to pair its sensors with the latter’s automated insulin delivery (AID) systems. million undiagnosed and 115.9

Insulin 105

Insulin FDA Approval Marketing Doctor 105

XTalks

NOVEMBER 22, 2022

Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.

Insulin 93

Insulin Drugs FDA Approval Immune Response 93

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. Since then, several more GLP-1 agonists have been approved by the FDA. And the demand won’t be easing anytime soon.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JUNE 10, 2024

The study explored efruxifermin’s potential in reducing liver fat, reversing fibrosis, enhancing insulin sensitivity and improving lipid profiles, representing a comprehensive treatment strategy for MASH. It not only reduces liver fat and inflammation but can also reverse fibrosis, enhance insulin sensitivity and improve lipid profiles.

Insulin 52

Insulin Life Science Regulation Hormones 52

XTalks

JULY 17, 2024

Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin. Excess GH stimulates the secretion of insulin-like growth factor-1 (IGF-1) from the liver, which causes most of the clinical manifestations of acromegaly.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

JUNE 5, 2023

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. As of May 2023, both Ozempic and Wegovy were on the FDA’s Drug Shortages list due to a global shortage of semaglutide.

FDA Approval 95

FDA Approval Containment Drugs Pharmacy 95

XTalks

APRIL 29, 2022

These bind to their respective receptors to increase glucose metabolism by increasing insulin secretion. Novo introduced a higher-dose version of Saxenda called Wegovy, which won FDA approval in 2021 for chronic weight management. Wegovy had a price tag of $1,297 a month when it was first launched.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

NOVEMBER 3, 2022

Demand for Lilly’s GIP/GLP-1 receptor agonist Mounjaro is also rising because of high patient demand since the drug’s May 13 FDA approval and expanding insurance coverage. Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter.

Sales 98

Sales FDA Approval Production Insulin 98

Pharmaceutical Technology

DECEMBER 22, 2022

The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. Sanofi wins the Product Launches award this year following the further development of its Dupixent (dupilumab) product and a string of approvals.

Insulin 130

Insulin Production Development Genetics 130

XTalks

FEBRUARY 21, 2024

There are currently no FDA-approved drug therapies for MASH, and the disease is characterized by excess fat accumulation and inflammation in the liver, which leads to liver scarring or fibrosis. It has been approved for treating diabetes and obesity.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JULY 4, 2024

Keytruda (Pembrolizumab) Keytruda 2023 Sales: $25.011 billion Company/Developer: Merck Date of First US Food and Drug Administration (FDA) Approval: September 4, 2014 Indications Keytruda Is FDA-Approved for: Unresectable or metastatic melanoma.

Sales 52

Sales Drugs FDA Approval Marketing 52

XTalks

AUGUST 30, 2024

The recent partnership to produce affordable insulin in Africa aims to reach over four million people by 2026, reflecting Novo Nordisk’s commitment to global health equity. Eli Lilly (LLY) Market Capitalization: $353.3 Billion Eli Lilly continues to strengthen its market position with innovative therapies and strategic acquisitions.

Marketing 90

Marketing Production Sales Antibody 90

XTalks

OCTOBER 11, 2023

They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion. Ozempic and Wegovy continue to be blockbusters for Novo, despite facing competition from Eli Lilly’s dual GLP-1/GIP agonist Mounjaro (tirzepatide), which won FDA approval in May 2022.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

XTalks

AUGUST 2, 2023

Paxlovid was first authorized under the FDA Emergency Use Authorization in December 2021 ; however, it has received FDA approval on May 25, 2023. pneumoniae serotypes) replaced the company’s first pneumococcal conjugate vaccine Prevnar (PCV7, approved by the FDA in February 2000) in a February 2010 FDA approval.

Sales 96

Sales Manufacturing FDA Approval Life Science 96

XTalks

JUNE 12, 2023

Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. Additionally, Abbott launched over 125 new products in 2022, in conjunction with a series of FDA approvals. These approvals reinforced the company’s position as a global leader in eye health. billion ($22.83 billion USD), a 20.65

FDA Approval 94

FDA Approval Production Sales In-Vitro 94

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Nizoral is prescribed off-label, while the others are FDA approved.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 17, 2020

In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. In the program, it was demonstrated that pro-insulin specific T cells from human subjects, which are prominent in patients with type 1 diabetes, could be effectively dampened with an Immuno-STAT.

Protein 94

Protein Engineer Immune Response In-Vivo 94

XTalks

FEBRUARY 2, 2023

Amgen’s Amjevita, the first biosimilar version of AbbVie’s blockbuster arthritis injection Humira (adalimumab), has finally hit the market this week after fetching US Food and Drug Administration (FDA) approval back in 2016. Alvotech’s biosimilar is pending FDA approval. Amjevita Launch: Cost Savings, But for Whom?

Marketing 52

Marketing FDA Approval Branding Drugs 52

XTalks

MAY 20, 2022

Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 Mounjaro’s FDA approval was based on data from five clinical trials either as a single therapy or in combination with other diabetes medications. percent more than insulin degludec and 1.0

Insulin 52

Insulin Life Science Drugs Sales 52

XTalks

FEBRUARY 14, 2024

US drug pricing has been under fire for many years and things took a significant turn last year when the three major insulin makers (Eli Lilly, Sanofi and Novo Nordisk) decided to slash the price of their insulin products and agreed to cap out-of-pocket costs at $35 per month for patients with insurance coverage.

Drugs 52

Drugs Insulin Pharmacy Development 52